logo
Permian Basin Veterans Honored in D.C.

Permian Basin Veterans Honored in D.C.

Yahoo30-05-2025
SAN ANGELO, Texas (Concho Valley Homepage) —Nearly 100 West Texas veterans recently traveled to Washington, D.C., on a three-day journey to visit the memorials built in their honor — a trip filled with reflection, remembrance and healing, made possible by the nonprofit Permian Basin Honor Flight.
The organization, based in West Texas, provides all-expenses-paid trips to Washington for local veterans to see the Korean War Veterans Memorial, Vietnam Veterans Memorial, World War II Memorial, and other sites of national significance. Veterans visited a total of 14 memorials and museums over the course of the trip.
Wesley Smith, who took over as flight director in 2023, said the program's goal is simple: to give these heroes the recognition and gratitude they deserve while there's still time.
'The Honor Flight is for us to bring those war heroes to this memorial, to the Korean Memorial, to the Vietnam Memorial before it's too late — to honor them and serve them and show them the respect that they so deserve, and to show them the world is changing,' Smith said. 'It's not going to be the same world these Vietnam vets came home to. And to show the Korean War vets they're never going to be forgotten. The history books tell them it's the 'forgotten war,' but it's not…'
Smith has been involved with the Honor Flight team since 2015 and served as board president from 2018 to 2019.
'absolutely love getting to lead men and women heroes to care for them and honor them with the upmost respect that they deserve,' he said.
The trip is made possible entirely through community fundraising and sponsorships. Each veteran's flight, lodging, meals, and transportation cost about $2,000 — none of which is charged to the veteran.
'So we have to raise that money all year long or these vets don't get to come up here,' Smith said. 'The last thing we want to do is say, 'Hey, you've been selected for a beautiful trip, but you owe us money.' And we're not going to do that. So it takes a community — it takes all community efforts to bring this together and make this happen
The emotional impact of the trip was evident in conversations with veterans and their guardians.
'Going through this and being out here and how therapeutic it is — and getting to kinda rehash some of the things and let some of the emotions out that maybe you've held up a long time — is great,' said Danny Davis of Midland, who volunteered as a guardian for the trip.
'To the workers, I would say thank you. Thank you from the bottom of my heart. I'm so grateful I was chosen for this flight, and I've enjoyed it,' said Trinand, a Vietnam veteran on the trip. 'The personnel, the people — our friends. They are my friends. We're brothers because of the war, but now we're friends because we have met.'
For some, the visit to the memorials brought back powerful memories — and a sense of closure.
'I would suggest that they all come here and visit the memorials,' said Vietnam veteran William Tolbert. 'I'm thoroughly enjoying it, and I wouldn't want to come here in the summertime, but it's really impressive.'
'Oh man, this trip has been awesome — just honoring our vets that set the pace for us, you know, led the way,' said Army veteran Manuel Payan. 'It's an honor just to be around them. And it's great to just make new friends, especially with people like that that served.'
In addition to moments of solemn reflection, the trip also included time for connection and celebration — from dancing to storytelling — as veterans connected and made new memories together.
The Permian Basin Honor Flight continues its mission through year-round fundraising to ensure future generations of veterans receive the honor and healing they've earned.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Virginia Task Force 1 returns home after victim recovery efforts in Texas flood zone
Virginia Task Force 1 returns home after victim recovery efforts in Texas flood zone

Yahoo

time7 hours ago

  • Yahoo

Virginia Task Force 1 returns home after victim recovery efforts in Texas flood zone

CHANTILLY, Va. () — Virginia Task Force 1 (VA TF-1), the commonwealth's specialized search and rescue team, is back home from working victim recovery operations following deadly floods in Texas. The crew of four people and three dogs returned to their home base in Chantilly just before noon Monday after a 17-day deployment. Deadly Texas floods leave officials pointing fingers after warnings missed Special handlers and human remains detection dogs from VA TF-1 searched tough terrain, through debris, floodwaters and riverbeds, every day for more than two weeks, working to recover people missing in the devastating floods. The highly trained team included canine specialists Kristi Bartlett and Charlotte Grove and their human remains detection dogs, Athena and Ivy. 'When you're searching 60 miles of shoreline, you're like, 'Okay, I'm trying to find a needle in a haystack.' But, every day we're still giving it our all, really searching and gridding out our areas,' Bartlett said. Grove and Ivy have been paired up on past deployments, working together in search and recovery efforts after Hurricane Ian ravaged Florida back in 2022. 'You still get surprised when you get there, at the amount of devastation that there actually was,' Grove said of her arrival in Texas. This time, the pair worked 12+ hour days sniffing and searching through debris and floodwater in the Texas heat. 'We just keep working. We want to keep working until every last person has been brought home,' Grove said. More than 160 people are still missing after deadly Texas floods, governor says 'We're definitely focused on the mission. Just trying to make sure that we bring closure for everybody and their loved ones,' Bartlett said. 'We're definitely tired. We want to get our life back to normal, but also do more training. So when the next disaster happens, [Athena] is ready to go back out the door.' While 10-year-old canine Athena may have more training ahead, 11-year-old canine Ivy is a bit older. Grove said this may have been Ivy's final deployment before she heads into retirement. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Yahoo

time8 hours ago

  • Yahoo

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025, at 12:30 p.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at A replay of the webcast will be available following the conclusion of the live broadcast. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

Yahoo

time8 hours ago

  • Yahoo

Natera Announces Launch of ABCSG 61 ("TEODOR"), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

Study utilizes Signatera to identify HR+, HER2-negative breast cancer patients for de-escalation of neoadjuvant chemotherapy AUSTIN, Texas, July 29, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness). TEODOR is a Phase II, multicenter, randomized controlled trial (RCT) that aims to replace chemotherapy with endocrine therapy prior to surgery for a subset of women with hormone receptor-positive (HR+), HER2-negative breast cancer, who are endocrine responsive and test negative with Signatera. Sponsored by the Austrian Breast & Colorectal Cancer Study Group (ABCSG), TEODOR expects to enroll approximately 250 patients across 15 sites in Austria. Previous studies have demonstrated that patients who test Signatera-negative at diagnosis and then receive chemotherapy have excellent outcomes, with risk of recurrence at less than 5%. In an effort to reduce pre-operative chemotherapy, which can carry significant side effects, this study is designed to evaluate the efficacy of endocrine therapy compared to chemotherapy in patients who are Signatera-negative. After a four-week course of endocrine therapy, patients who are Signatera-negative and show a favorable endocrine sensitivity as measured by the Ki-67 proliferation index will be randomized to receive either additional endocrine therapy or chemotherapy. The primary endpoint of the study is the rate of neoadjuvant therapy response, assessed via pathological complete response (pCR) and modified Preoperative Endocrine Prognostic Index (PEPI) score across the endocrine therapy and chemotherapy arms of the trial. Secondary endpoints include long-term outcomes such as breast cancer recurrence and overall survival. "TEODOR is designed to examine whether we can use endocrine responsiveness and ctDNA status to optimize systemic therapy in the neoadjuvant setting," said ABCSG President, Michael Gnant, M.D., FACS, FEBS, who serves as professor of surgery, Comprehensive Cancer Center, Medical University of Vienna, and principal investigator of the TEODOR trial. "This study marks a critical step toward more personalized medicine, leveraging the latest technologies to improve patient care." "With the TEODOR trial, our goal is to identify patients who may be able to safely forgo chemotherapy," said Angel Rodriguez, M.D., medical director of oncology at Natera. "We are proud to collaborate with ABCSG on this important trial, and we hope this study will support the role of Signatera in guiding neoadjuvant therapy in breast cancer." About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit About ABCSG The ABCSG (Austrian Breast & Colorectal Cancer Study Group) is Austria's largest and best-known academic research organization, successfully conducting international clinical trials on breast and colorectal cancer — and, since 2013, also on pancreatic cancer. In addition, ABCSG is increasingly active in translational research. Our goal is to standardize diagnostics, treatment, and follow-up care throughout Austria and to offer patients the best and most up-to-date therapies. Since 1984, approximately 29,000 patients have participated in ABCSG studies worldwide. Multidisciplinarity is key to our global success and has helped improve cure rates and survival. Our clinical trials and translational research projects are conducted transparently and are monitored at every stage by ethics committees, regulatory authorities, and our highly professional and dedicated ABCSG team. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store